Liao C, Liang X, Zhang X, Li Y
Some people taking GLP-1 medications may experience digestive side effects, with these being the most common: Nausea, especially at the start or after a dose increase Heartburn or stomach discomfort after meals Constipation, which can occur as the body adjusts Diarrhea, which may be mild or bothersome Vomiting, sometimes along with nausea Most digestive side effects lessen as the body adjusts
Postbiotics, the metabolic byproducts of bacteria rather than the bacteria themselves, are emerging as an alternative approach
This large cohort study used data on more than 145,000 people treated with GLP-1 agonists, and almost 292,000 people treated with DPP4 inhibitors from Norway, Sweden and Denmark
Dulaglutide, liraglutide and subcutaneous semaglutide have been approved for reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus with established cardiovascular disease, dulaglutide is approved for use in type 2 diabetes mellitus with multiple risk factors, and both liraglutide and semaglutide have been approved for chronic weight management
Patients who want to lose fat while protecting lean mass should work with a provider who builds muscle-preservation strategies into the plan from the beginning
